Xyntha® (antihemophilic factor [recombinant]) - Prior Authorization/Medical Necessity - UnitedHealthcare Commercial Plansopen_in_new
Defines UnitedHealthcare commercial plan prior authorization and medical necessity criteria for initiation and reauthorization of Xyntha for treatment of Hemophilia A (congenital Factor VIII deficiency) in adults and children, including required documentation, trial/failure or hypersensitivity to alternative recombinant factor products, high-risk/inhibitor considerations, and authorization durations.
Annual review with no changes to coverage criteria reported for 9/2025.
Revised outline of coverage criteria in 9/2024 without change to clinical intent.
Modified physician attestation to prescriber attestation in 9/2023.
Added Advate and Recombinate as preferred/alternative agents in 9/2020.
Program originally created 10/2016 and implemented 11/16/2025 effective date.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.